Sun Pharmaceuticals Industries Ltd's Q4FY25 Quarterly Results

Result Summary

• Sun Pharmaceuticals Industries Ltd reported a 11.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.4%.
• Its expenses for the quarter were down by 6.5% QoQ and up 8.8% YoY.
• The net profit decreased 8.7% QoQ and increased 34.1% YoY.
• The earnings per share (EPS) of Sun Pharmaceuticals Industries Ltd stood at 11.1 during Q4FY25.

Financial Statments for Q4FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharmaceuticals Industries Ltd is a prominent player in the pharmaceutical industry, known for its extensive range of pharmaceutical products and formulations. The company specializes in producing a variety of generic drugs and therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, and diabetology. Sun Pharma has established itself as a leader in the global pharmaceutical market, with a significant presence in both the domestic and international sectors. Recent developments in the company may include strategic acquisitions, collaborations, or expansions in new geographical markets to enhance its operational capabilities and product offerings, although specific developments were not provided in the current data.

Revenue

In the fourth quarter of fiscal year 2025 (Q4FY25), Sun Pharmaceuticals Industries Ltd reported a total income of ₹12588.84 crores. This represents a decline of 11.0% quarter-over-quarter (QoQ) from the previous quarter (Q3FY25), where total income was ₹14141.08 crores. However, on a year-over-year (YoY) basis, there was an increase of 11.4% compared to the fourth quarter of the previous fiscal year (Q4FY24), which recorded a total income of ₹11303.95 crores. These figures reflect the company's capacity to generate revenue amidst changing market conditions and operational dynamics.

Profitability

For Q4FY25, Sun Pharmaceuticals Industries Ltd reported a profit before tax of ₹2815.52 crores, which is a 19.0% decrease compared to Q3FY25's ₹3476.40 crores. However, when compared to Q4FY24, this indicates a significant increase of 25.7% from ₹2239.69 crores. The profit after tax for Q4FY25 stood at ₹2658.74 crores, marking an 8.7% decrease QoQ from ₹2912.98 crores in Q3FY25, yet a robust 34.1% increase YoY from ₹1982.90 crores in Q4FY24. The earnings per share for Q4FY25 were ₹11.10, a decrease of 8.3% from the previous quarter's ₹12.10, but an increase of 33.7% from Q4FY24's ₹8.30. These metrics provide a clear snapshot of the company's profitability and its changes over the respective periods.

Operating Metrics

Total expenses for Sun Pharmaceuticals in Q4FY25 amounted to ₹9671.68 crores, which is a decrease of 6.5% compared to Q3FY25's total expenses of ₹10348.51 crores. On a YoY basis, there is an 8.8% increase from the total expenses of ₹8892.81 crores in Q4FY24. The tax expense for Q4FY25 significantly decreased by 73.4% QoQ from ₹558.86 crores in Q3FY25 to ₹148.93 crores, and also showed a 33.2% decrease from Q4FY24's ₹222.91 crores. These figures reflect the operational efficiency and cost management strategies of the company during this period, providing insights into its financial health and operational metrics.